



(公社) 日本薬理学会
理事長 赤羽 悟美



FIRST ANNOUNCEMENT

Dementia Therapeutics and Cognitive Rehabilitation

**University of Calabria, Rende (Cosenza), Italy
November 21st-23rd, 2022**

A Collaborative Scientific Initiative of

The University of Calabria, Rende (Cosenza), Italy,
The University Magna Graecia, Catanzaro, Italy,
The Tohoku Medical and Pharmaceutical University, Sendai, Japan,
Daiichi University of Pharmacy, Fukuoka, Japan,
Sant'Anna Institute for Neurological Rehabilitation, Kroton, Italy

Under the Auspices of

Italian Society of Pharmacology (SIF)
Japanese Society of Pharmacology (JPS)
Italian Society of Neurological Rehabilitation (SIRN)
World Federation of Neurorehabilitation (WFNR)

Presidents

Giacinto Bagetta (Rende, Cosenza)
Shinobu Sakurada (Sendai)

International Organizing Committee

Giacinto Bagetta (Rende, Cosenza)
Maria Tiziana Corasaniti (Catanzaro)
Pierluigi Nicotera (Bonn)
Tsukasa Sakurada (Fukuoka)
Paolo Tonin (Kroton)

Keynote Speakers & Chairs

Lucio Annunziato (Naples)
Giambattista Bonanno (Genoa)
Linda Clare (Exeter)

Monica Di Luca (Milan)
Chiara Fenoglio (Milan)
Sabatino Maione (Naples)
Luigi A. Morrone (Rende, Cosenza)
Pierluigi Nicotera (Bonn)
Domenico Pellegrini Giampietro
(Florence)
Marzia Perluigi (Rome)
Giorgio Racagni (Milan)
Tsukasa Sakurada (Fukuoka)
Paolo Tonin (Kroton)

International Scientific Secretariat

Hirokazu Mizoguchi (Sendai)
Luigi A. Morrone (Rende, Cosenza)

MEETING RATIONALE

The global impact of dementia is increasingly worrisome and up to 90% of dementia patients in low- and middle-income countries are not diagnosed with further delays in diagnosis due to the pandemic during which these fragile population pays the highest price.

Alzheimer's disease (AD) is the most common accounting for about two-thirds of all cases, but mixed forms of dementia are being increasingly recognized, making dementia a public health priority. These different forms may at least in part be explained through progressive alterations of the epigenome that may contribute to the decrease of cognitive abilities with advancing age.


Indeed, there is little doubt that AD is a multifactorial disease, which involves diverse pathogenic mechanisms and will probably require combinatorial therapies. Although many pathological factors, such as accumulation of protein aggregates of amyloid-beta (Ab) and tau, have been identified, their role in combination with other factors, at different disease stages, requires further clarification. A comprehensive understanding of the

complex disease mechanisms, the identification of early disease markers aided by ultrastructural magnetic resonance imaging are necessary to develop more effective treatments.

Although multiple failures of phase III trials with agents targeting Ab had initially been disappointing, the accelerated approval of aducanumab has recently renewed the interest in targeting Ab. The gain of information from the real-world data on aducanumab may anticipate that further development of clinical trials in AD will be prompted.

Actually, current treatments of AD provide only limited symptomatic effects and development of neuropsychiatric symptoms (NPS), other than cognitive symptoms, do affect some 97% dementia patients and they are managed with potentially harmful antipsychotics. The latter NPS are at least in part linked to unrelieved pain remarkably reducing quality of life. Hence, studies for the management of NPS are needed and novel opportunities are offered by complementary analgesic and non-BDZ anxiolytic effects of natural products such as phytocomplexes engineered to be trialed in double blind studies also for cognitive rehabilitation.

All the above illustrated topics and more, concerned with cognitive rehabilitation, are the subjects of the meeting.



General Information

Registration fee

A registration fee of 150 € is to be paid beforehand via bank transfer (IBAN: IT35W0200880884000103544669) to: Department of Pharmacy, Health Sciences and Nutrition, University of Calabria, 87036 Rende, Cosenza, Italy (causal: registration fee meeting “Dementia Therapeutics and Cognitive Rehabilitation”). The fee will allow to attend the meeting sessions. To limit the environmental impact of the meeting, the program will be available online by means of a QR code to be used with the smartphone.

Language

The language of the meeting will be English, no translation will be available.

Meeting content and format

The meeting is organized in basic, translational and clinical sessions on dementia. Each session is preceded by a keynote speech of 25 minutes duration including discussion. The sessions include oral presentations of 20 minutes duration including discussion.

The poster session will be Tuesday 22nd November. Posters will be discussed at lunch break, but they will be on display for all the duration of the meeting.

Accommodation

Accommodation for participants will be at an agreed discount rate at the four stars San Francesco Hotel, Rende (Cosenza). Transportation to/from the University will be available free of charge for registered participants from the Hotel San Francesco.

For further information, please, address the correspondence to: g.bagetta@unical.it

Executive Secretariat at: Department of Pharmacy, Health Sciences and Nutrition, University of Calabria, 87036 Rende, Cosenza, Italy